Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma
NCT ID: NCT00286013
Last Updated: 2022-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
24 participants
INTERVENTIONAL
2004-05-01
2008-07-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Association of gemcitabine, oxaliplatin and radiotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* WHO performance status of 0 or 1
* Complete recovrey from surgery in case an enteric and/or biliary tract by-pass operation has been performed
* Maximum delay after surgery: 8 weeks
* No previous or co-existent malignant disease except non melanoma skin cancers and adequately treated cervic carcinoma in situ
* Adequate bon marrow reserve
* No previous chemotherapy or radiotherapy
* Expected survival \> 6 months
Exclusion Criteria
* Metastatic disease
* Inadequate liver function after derivative surgery
* Inadequate renal function
* Pregnancy, breast feeding
* Use of any other investigational agent in the month before enrollment
* Patients with grade 2 or more neuropathy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Ghent
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marc Peeters, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Ghent
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Erasme University Hospital
Brussels, , Belgium
Jules Bordet Institute
Brussels, , Belgium
University Hospital Ghent
Ghent, , Belgium
CHU Sart-Tilman
Liège, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Website University Hospital Ghent
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2004/196
Identifier Type: -
Identifier Source: org_study_id